Drug-resistant bacteria spread in Bangladesh ICUs
Analysis based on 7 articles · First reported Jul 25, 2026 · Last updated Jul 25, 2026
The findings highlight a public health crisis in Bangladesh that could increase healthcare costs and strain resources, but the demonstrated effectiveness of infection control measures offers a path to mitigate impact. No direct financial market impact is expected, though pharmaceutical companies producing antibiotics may face regulatory or demand shifts.
Two studies by the Icddr,b (icddr,b) reveal that over half of ICU patients initially free from difficult-to-treat drug-resistant Gram-negative bacteria acquire them during hospital care in Bangladesh — Dhaka Division, Bangladesh. The studies, funded by the United States — Centers for Disease Control and Prevention and published in Microbiology Spectrum and Antimicrobial Resistance & Infection Control, analyzed 373 adults and 363 neonates at a tertiary government hospital. They found 48.5% of ICU patients colonized with resistant bacteria, 53% of initially free patients acquiring colonization, and over 90% mortality among those with culture-confirmed infections. A second study showed that a targeted infection prevention and control program in a NICU reduced bloodstream infections by 86% and mortality from 26 to 4 per 100 admissions. Researchers including Gazi Md Salahuddin Mamun, Fahmida Chowdhury, and Tahmeed Ahmed emphasize the need for strengthened infection control, hygiene, and antibiotic stewardship.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard